JP2015502137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502137A5 JP2015502137A5 JP2014534774A JP2014534774A JP2015502137A5 JP 2015502137 A5 JP2015502137 A5 JP 2015502137A5 JP 2014534774 A JP2014534774 A JP 2014534774A JP 2014534774 A JP2014534774 A JP 2014534774A JP 2015502137 A5 JP2015502137 A5 JP 2015502137A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- variant
- nucleic acid
- enzyme
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 92
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 92
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 46
- 150000007523 nucleic acids Chemical class 0.000 claims description 45
- 230000035772 mutation Effects 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 41
- 102000039446 nucleic acids Human genes 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 34
- 108090000790 Enzymes Proteins 0.000 claims description 32
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 24
- 102000003436 UBA3 Human genes 0.000 claims description 22
- 108060008744 UBA3 Proteins 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 239000012472 biological sample Substances 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 206010059866 Drug resistance Diseases 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 6
- 239000002853 nucleic acid probe Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 102000038427 NEDD8-activating enzyme E1 Human genes 0.000 claims description 2
- 108091007790 NEDD8-activating enzyme E1 Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000012875 competitive assay Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims 5
- 239000002532 enzyme inhibitor Substances 0.000 claims 5
- 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 claims 2
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 claims 2
- 108010092778 Autophagy-Related Protein 7 Proteins 0.000 claims 1
- 108050008316 DNA endonuclease RBBP8 Proteins 0.000 claims 1
- 101000630572 Homo sapiens Molybdopterin-synthase sulfurtransferase Proteins 0.000 claims 1
- 101000608584 Homo sapiens Ubiquitin-like modifier-activating enzyme 5 Proteins 0.000 claims 1
- 101000662020 Homo sapiens Ubiquitin-like modifier-activating enzyme 6 Proteins 0.000 claims 1
- 101000662026 Homo sapiens Ubiquitin-like modifier-activating enzyme 7 Proteins 0.000 claims 1
- 102100026101 Molybdopterin-synthase sulfurtransferase Human genes 0.000 claims 1
- 102100035250 SUMO-activating enzyme subunit 2 Human genes 0.000 claims 1
- 102100039197 Ubiquitin-like modifier-activating enzyme 5 Human genes 0.000 claims 1
- 102100037939 Ubiquitin-like modifier-activating enzyme 6 Human genes 0.000 claims 1
- 102100037938 Ubiquitin-like modifier-activating enzyme 7 Human genes 0.000 claims 1
- 102100022979 Ubiquitin-like modifier-activating enzyme ATG7 Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 239000013610 patient sample Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544843P | 2011-10-07 | 2011-10-07 | |
| US61/544,843 | 2011-10-07 | ||
| US201261596420P | 2012-02-08 | 2012-02-08 | |
| US61/596,420 | 2012-02-08 | ||
| PCT/US2012/058983 WO2013052814A2 (en) | 2011-10-07 | 2012-10-05 | E1 enzyme mutants and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015502137A JP2015502137A (ja) | 2015-01-22 |
| JP2015502137A5 true JP2015502137A5 (enExample) | 2015-11-26 |
Family
ID=48044414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534774A Pending JP2015502137A (ja) | 2011-10-07 | 2012-10-05 | Ｅ１酵素変異体およびその用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150030601A1 (enExample) |
| EP (1) | EP2764121A4 (enExample) |
| JP (1) | JP2015502137A (enExample) |
| WO (1) | WO2013052814A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2923752A1 (en) * | 2013-05-14 | 2014-11-20 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
| CA2916468C (en) * | 2013-07-02 | 2019-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| JP6421369B2 (ja) * | 2014-05-16 | 2018-11-14 | 国立大学法人神戸大学 | 迅速かつ高感度な多重免疫染色法 |
| EP3684363A4 (en) | 2017-09-21 | 2021-05-12 | Millennium Pharmaceuticals, Inc. | CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES |
| WO2022056252A1 (en) * | 2020-09-10 | 2022-03-17 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods for treating hyperglycemia in type-2 diabetes |
| WO2025073926A1 (en) * | 2023-10-05 | 2025-04-10 | Københavns Universitet | An inhibitor of sumo e1-enzyme for use in tissue regeneration |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040043386A1 (en) * | 2002-08-30 | 2004-03-04 | Todd Pray | Methods and compositions for functional ubiquitin assays |
| US20070059720A9 (en) * | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
| SI1848718T1 (sl) * | 2005-02-04 | 2012-12-31 | Millennium Pharmaceuticals, Inc. | Inhibitorji E1 aktivacijskih enzimov |
| JP5231251B2 (ja) * | 2006-02-02 | 2013-07-10 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｅ１活性化酵素の阻害剤 |
| CA2659894C (en) * | 2006-08-08 | 2018-03-27 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
-
2012
- 2012-10-05 US US14/349,843 patent/US20150030601A1/en not_active Abandoned
- 2012-10-05 EP EP12838184.5A patent/EP2764121A4/en not_active Withdrawn
- 2012-10-05 WO PCT/US2012/058983 patent/WO2013052814A2/en not_active Ceased
- 2012-10-05 JP JP2014534774A patent/JP2015502137A/ja active Pending
-
2016
- 2016-06-01 US US15/170,328 patent/US20170107579A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108138222B (zh) | 表观遗传染色体相互作用 | |
| JP6076581B2 (ja) | Ｔｉａｂｓを検出するための組成物及び方法 | |
| CA2948351C (en) | Biomarkers for response to pi3k inhibitors | |
| US10697022B2 (en) | PIK3CA novel mutations detection for diagnosis of acquired cetuximab resistance in metastatic colorectal cancer patients | |
| JP5586607B2 (ja) | ２０個の遺伝子パネルを用いて潰瘍性大腸炎及び関連疾患を評価し治療するためのマーカー及び方法 | |
| JP2007506426A5 (enExample) | ||
| JP2015502137A5 (enExample) | ||
| JP2016540033A (ja) | 新規ケモカイン受容体、ｃｘｃｒ８の同定 | |
| Sun et al. | Genetics of obesity in East Asians | |
| CA2683071A1 (en) | A method for detecting the binding between mdm2 and the proteasome | |
| JP2010259438A5 (enExample) | ||
| JP2021508700A (ja) | Ａｔｒ阻害剤を使用するがん処置の方法 | |
| JP2009544583A (ja) | Ｔａｋ１阻害剤を用いた癌の治療方法 | |
| WO2013172926A1 (en) | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer | |
| JP2014533114A5 (enExample) | ||
| Xu et al. | Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas | |
| JP7036594B2 (ja) | Ｂｒａｆ陽性癌を患っている患者を、ｂｒａｆ阻害剤に対する非レスポンダーであると及びｍａｐｋ／ｅｒｋ阻害剤に対するレスポンダーであると同定する手段及び方法 | |
| Liu et al. | Association between EGFR polymorphisms and the risk of lung cancer | |
| CN105734070A (zh) | Corin基因变异体及其用途 | |
| TWI465720B (zh) | 預測神經發育、神經的或神經精神性病症治療之臨床效益之方法 | |
| CN106573967A (zh) | 表皮生长因子受体基因的胞外域iii中的突变 | |
| Nanba et al. | The allelic distribution of a single nucleotide polymorphism in the PDCD5 gene locus of Japanese non-small cell lung cancer patients | |
| Asad et al. | Evaluation of Single Nucleotide Variants in Ethiopian Patients with Atopic Dermatitis. | |
| Rodius et al. | Matrix metalloproteinase 9 polymorphism and outcome after myocardial infarction | |
| KR20140044329A (ko) | Kiaa1456 발현의 결장암 환자 생존에 대한 예측 |